计算溶液所需的质量、体积或浓度。
Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB 2 receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity
In Vivo
Etrinabdione (i.p.; 20?mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. Etrinabdione can also significantly ameliorate glucose tolerance, reduce leptin levels (a marker of adiposity) and increase adiponectin and incretins (GLP-1 and GIP) levels . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:PPARγ CB2